Testing for MRD With ctDNA in Colorectal Cancer (CRC)

Opinion
Video

A panel of medical oncologists introduce themselves and provide an overview of circulating tumor DNA (ctDNA) and how it relates to MRD (minimal residual disease) testing in colorectal cancer (CRC).

Recent Videos
4 experts in this video
4 experts in this video
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
5 experts in this video
4 experts in this video
5 experts in this video
4 experts in this video
5 experts in this video
Related Content